Here's a look at some of the latest news regarding ophthalmic drugs and therapies from the past week.
- Global biopharmaceutical company AbbVie announced last week that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for Humira® (adalimumab) for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids or in whom corticosteroid treatment is inappropriate.
- In a recent press release, QBioMed provided an update on the drug development program for MAN-01 for the treatment of Primary Open Angle Glaucoma (POAG) through its technology partner company Mannin Research Inc., stating pre-clinical lead candidate optimization of a small molecule for topical application had been initiated and lead candidate selection was progressing on-time.
- RegeneRx Biopharmaceuticals, Inc. and Lee's Pharmaceutical Holdings Ltd., recently announced acceleration of development of RGN-259 in China. RGN-259 is RegeneRx's Tβ4-based ophthalmic drug candidate being developed for dry eye syndrome and for the treatment of neurotrophic keratopathy (NK), both of which are being developed in the U.S through its joint venture, ReGenTree.
- And yesterday, EyeGate Pharmaceuticals, Inc. announced interim data from its Phase 1b/2a trial evaluating its lead product candidate, iontophoretic EGP-437, in the treatment of ocular inflammation and pain in cataract surgery patients. The company reported encouraging data, with all subjects experiencing low pain throughout the duration of the trial.